Metropolis Healthcare (METROPOLIS) Q1 26/27 earnings summary

Executive summary

• Q1 FY27 delivered 17% year-on-year revenue growth to INR 450 crore, with EBITDA up 27% and PAT up 26%, driven by patient and test volume increases, margin expansion, and network growth.

• Expansion in Tier 2 and Tier 3 cities, integration of recent acquisitions, and a focus on specialty diagnostics and digital transformation supported performance.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved and reviewed without qualification by statutory auditors.

• The company operates primarily in the pathology services segment, with recent business acquisitions expanding its footprint.

• The company remains optimistic about sustaining double-digit growth and margin improvement, anchored by a robust pipeline of organic and inorganic initiatives.

Financial highlights

• Revenue reached INR 450 crore (Rs. 4,502.15 million), up 17% year-on-year; EBITDA grew 27% to INR 113 crore, with margin expanding 210 bps to 25.2%.

• PAT stood at INR 57 crore (Rs. 568.83 million), up 26% year-on-year, with PAT margin at 12.6%.

• B2C revenue grew 18%, B2B by 15%; patient volumes rose 10% to 3.7 million, test volumes 11% to 7.8 million.

• Specialty diagnostics contributed 40% of revenue (up 17%), TruHealth 18% (up 22%).

• Earnings per share (consolidated, basic and diluted) for Q1 FY27 were Rs. 2.73, up from Rs. 2.17 in Q1 FY26.

Outlook and guidance

• Revenue growth guidance for FY 2027 is 14%-16%, primarily volume-driven.

• EBITDA margin expected to improve by 100-150 bps in FY 2027, targeting 27%-28% over the next two years.

• Medium-term CAGR guidance remains at 14%-15%, with 9%-10% from patient volume growth and the rest from product mix.

• Continued focus on profitable, science-led growth and expanding into adjacencies.

• The sale and transfer of the External Quality Assessment Services Business to a wholly owned subsidiary is expected to be completed within two additional months.